AHL
ESPR

Abel Hall LLC’s Esperion Therapeutics ESPR Stock Holding History

Abel Hall LLC’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9K Buy
14,521
+2,025
+16% +$5.67K 0.01% 902
2026
Q1 		$34.2K Sell
12,496
-16,447
-57% -$52.1K 0.01% 770
2025
Q4 		$107K Buy
28,943
+16,801
+138% +$54.3K 0.03% 607
2025
Q3 		$32.2K Sell
12,142
-170
-1% -$329 0.01% 308
2025
Q2 		$12.1K Buy
+12,312
New +$12.3K 0.01% 280

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Abel Hall LLC's ESPR Position: Q2 2026 in Review

Abel Hall LLC increased its Esperion Therapeutics (ESPR) stake by 16% in Q2 2026, buying an estimated $5.67K and bringing the position to 14,521 shares worth $45.9K. The position accounts for 0.01% of the portfolio, ranked #902.

Abel Hall LLC first reported a position in ESPR in Q2 2025 and has held it in 5 quarters since. The position peaked at $107K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Abel Hall LLC held 14,521 shares of Esperion Therapeutics worth $45.9K as of Q2 2026.
  • Abel Hall LLC bought 2,025 Esperion Therapeutics shares in Q2 2026, an estimated $5.67K.
  • Esperion Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #902 holding.
  • Abel Hall LLC first reported a position in Esperion Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Abel Hall LLC's Esperion Therapeutics position peaked at $107K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.